6000 Shoreline Ct, Ste 300
South San Francisco, CA 94080-7606
Veracyte is pioneering the emerging field of molecular cytology. We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. Our Goal: Enable Doctors to Make More Informed Treatment Decisions We aim to enable decision making that improves the quality of patient care and provide savings to the healthcare system. We are committed to developing molecular tests for oncology that are designed to clarify ambiguous results obtained from cytology samples. Our Focus: Molecular Cytology Our solution permits diagnoses to be made without surgery by using small samples collected by minimally invasive techniques such as fine needle aspiration (FNA). We use a whole-genome approach to identify genes that best differentiate benignity and malignancy. We have developed a molecular database of more than one billion genomic measurements. Our Team: Significant Depth of Expertise and Proven Leadership Our management team has industry-leading experience in discovery research, building robust clinical programs and commercializing high-value diagnostic tests. We are supported by a strong team of investors with extensive experience in building transformational healthcare and molecular diagnostic companies.